Trial Profile

A prospective, randomised, multicentre, open label phase III study of active specific immunotherapy with racotumomab plus best support treatment versus best support treatment in patients with advanced non-small cell lung cancer (NSCLC)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 31 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Sep 2018 Results published in the Journal of Clinical Oncology
06 Sep 2018 According to an Ariana Pharma media release, Recombio have an ongoing collaboration to apply KEM (Knowledge Extraction and Management) patient stratification technology to identify patients from the PROACTIVE clinical trial most benefiting from Racotumomab.
28 Jul 2016 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com